Login / Signup

Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5-6 years.

Ludovic TréluyerElodie Zana-TaiebPierre-Henri JarreauValérie BenhammouPierre KuhnMathilde LetouzeyLaetitia Marchand-MartinWes OnlandVéronique PierratLauren SaadePierre Yves AncelHeloise Torchin
Published in: Archives of disease in childhood. Fetal and neonatal edition (2024)
In children born before 32 weeks' gestation, doxapram treatment for apnoea of prematurity was not associated with neurodevelopmental disabilities.
Keyphrases
  • preterm infants
  • low birth weight
  • gestational age
  • positive airway pressure
  • young adults
  • obstructive sleep apnea
  • combination therapy
  • insulin resistance
  • smoking cessation
  • glycemic control